Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas
Howard A. Fine(Cornell University), Craig B. Borkowf(Center for Cancer Research), Elene Viscosi(Center for Cancer Research), Elizabeth A. Maher(Southwestern Medical Center), Tracy T. Batchelor(Brigham and Women's Hospital), Benjamin Purow(University of Virginia Health System), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics), William D. Figg(National Cancer Institute), Patrick Y. Wen(Dana-Farber Cancer Institute)
Cited by 174
Related Papers
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Malignant glioma: genetics and biology of a grave matter
|Genes & Development|2001|1.2k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k